ALS drug will be pulled from Canada, U.S. markets after failed trial – National
Descrease article font size Increase article font size Amylyx Pharmaceuticals will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial. The drugmaker on Thursday also announced a 70 per cent reduction in its workforce. It … Read more
